Moderna Shares Surge 177% on mRNA Melanoma Therapy Trial Results
Moderna and Merck announced Wednesday that their experimental mRNA cancer therapy demonstrated clinically meaningful improvement in treating high-risk melanoma patients, triggering a 177% surge in Moderna shares and a 12.6% rise in Merck stock. The combination therapy, called intismeran paired
MRNA-5.13%
LucasBennett·08-19 20:23
